You are here

7 Hills Pharma LLC

Company Information
Address
2126 Sheridan St
Houston, TX 77030
United States



Information

UEI: CJJ6DE7APKY6

# of Employees: 1


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Integrin Activation to Augment SARS-CoV-2 Vaccination

    Amount: $297,724.00

    Abstract On March 11, 2020 the World Health Organization (WHO) announced a global Coronavirus Disease 2019 (COVID-19) pandemic. The disease is characterized by severe flu-like symptoms, with advanced ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  2. A small molecule integrin activator to enhance cord blood transplant

    Amount: $1,864,898.00

    PROJECT SUMMARY This proposal is in response to the parent announcement for Phase II STTR (R42) grant applications. Hematopoietic stem cell transplantation has become a preferred treatment for hematol ...

    STTRPhase II2020Department of Health and Human Services National Institutes of Health
  3. Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors

    Amount: $2,000,000.00

    PROJECT SUMMARY/ABSTRACT Immune checkpoint inhibitors (CPIs), such aPD-1 agents (nivolumab, and pembrolizumab), are the current standard of care treatment for the frontline management of advanced mela ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  4. Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies

    Amount: $243,282.00

    Leukocyte adhesion deficiency type ILADis a rare and often fatal primary immunodeficiencyIt is caused by autosomal recessive mutations in the gene ITGBwhich encodes CDthe commonsubunitof thefamily of ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  5. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    Amount: $2,001,399.00

    Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer imm ...

    STTRPhase II2018Department of Health and Human Services National Institutes of Health
  6. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    Amount: $313,705.00

    DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and progra ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  7. A small molecule integrin activator to enhance cord blood transplant

    Amount: $295,931.00

    DESCRIPTION provided by applicant This proposal is in response to PA the parent announcement for STTR R grant applications Hematopoietic stem cell transplantation has become a preferre ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government